Heron Therapeutics (NASDAQ:HRTX) Now Covered by Stifel Nicolaus

Analysts at Stifel Nicolaus started coverage on shares of Heron Therapeutics (NASDAQ:HRTX) in a note issued to investors on Monday, TipRanks reports. The firm set a “buy” rating and a $21.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price points to a potential upside of 42.76% from the stock’s previous close.

Several other research analysts have also commented on HRTX. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 23rd. Needham & Company LLC reiterated a “buy” rating and set a $44.00 price target on shares of Heron Therapeutics in a report on Wednesday, April 15th. Zacks Investment Research lowered Heron Therapeutics from a “buy” rating to a “hold” rating and set a $18.00 price target on the stock. in a report on Wednesday, May 20th. FIX assumed coverage on Heron Therapeutics in a report on Monday, May 18th. They set an “add” rating on the stock. Finally, Guggenheim started coverage on Heron Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $24.00 price target on the stock. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $36.10.

Shares of HRTX stock opened at $14.71 on Monday. The stock’s fifty day moving average is $18.33 and its two-hundred day moving average is $18.49. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.17 and a current ratio of 4.53. The firm has a market capitalization of $1.33 billion, a P/E ratio of -6.48 and a beta of 1.55. Heron Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $26.81.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.08. Heron Therapeutics had a negative return on equity of 56.85% and a negative net margin of 138.31%. The business had revenue of $25.40 million for the quarter, compared to analyst estimates of $21.23 million. During the same quarter in the previous year, the firm earned ($0.80) EPS. The company’s quarterly revenue was down 19.6% compared to the same quarter last year. On average, equities analysts forecast that Heron Therapeutics will post -2.33 earnings per share for the current year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Redmond Asset Management LLC raised its holdings in Heron Therapeutics by 1.5% in the 1st quarter. Redmond Asset Management LLC now owns 46,535 shares of the biotechnology company’s stock valued at $546,000 after buying an additional 689 shares during the period. Great West Life Assurance Co. Can grew its position in Heron Therapeutics by 19.9% in the 4th quarter. Great West Life Assurance Co. Can now owns 6,097 shares of the biotechnology company’s stock valued at $142,000 after acquiring an additional 1,010 shares in the last quarter. Cutter & CO Brokerage Inc. grew its position in Heron Therapeutics by 3.6% in the 1st quarter. Cutter & CO Brokerage Inc. now owns 29,725 shares of the biotechnology company’s stock valued at $349,000 after acquiring an additional 1,040 shares in the last quarter. Principal Financial Group Inc. grew its position in Heron Therapeutics by 7.4% in the 1st quarter. Principal Financial Group Inc. now owns 22,884 shares of the biotechnology company’s stock valued at $269,000 after acquiring an additional 1,572 shares in the last quarter. Finally, M&T Bank Corp grew its position in Heron Therapeutics by 15.9% in the 1st quarter. M&T Bank Corp now owns 12,741 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 1,744 shares in the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: Current Ratio

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.